Metabolic dysfunction-associated steatotic liver disease affects an estimated 30 percent of adults worldwide, developing silently without alcohol consumption and often going unnoticed until advanced liver scarring occurs. Recent clinical data show that rising rates among younger adults and missed follow-up appointments highlight a critical gap in preventive screening.
The assumption that liver disease is strictly tied to heavy drinking leaves millions vulnerable to silent progressive damage. In clinical practice, physicians increasingly encounter patients with fatty liver with no history of alcohol use, according to Dr. Jaya Agarwal, consultant and assistant professor of gastrointestinal surgery at Amrita Hospital in Faridabad. Many of these individuals are young professionals who feel entirely well and discover the condition only during routine medical evaluations.
Global Prevalence and Rising Rates Among Younger Adults
Known formally as metabolic dysfunction-associated steatotic liver disease, or MASLD, the condition affects roughly 30 percent of adults globally, drawing from a 2023 analysis published in Hepatology cited by the Hindustan Times. Regional data underscore how deeply the condition reaches into younger demographics. Research from the Korea Disease Control and Prevention Agency shows that MASLD prevalence among adults aged 19 to 44 climbed from 22.3 percent across 2007–2009 up to 30.5 percent during 2022–2023, as detailed by Sports Chosun.
This upward trend extends to individuals in their 20s, where the prevalence rate has grown by approximately 1.5 times over the past decade. Experts link this spread among younger populations to rising obesity rates, sedentary routines, high-calorie diets rich in refined carbohydrates, and increased consumption of sweetened carbonated beverages. Smoking also compounds these risks; research led by Professor Lee Moon-hyung found that smokers exhibited a 14 percent higher risk of fatty liver than nonsmokers due to altered insulin resistance.
Daily Habits and Hidden Metabolic Risk Factors
Metabolic dysfunction occurs when the body stops responding effectively to insulin, prompting the liver to store excess fat. While obesity and type 2 diabetes remain primary drivers, everyday routines contribute significantly to this metabolic strain. Late-night dining accompanied by large portions of heavy foods and sugary desserts disrupts energy balance, while packaged fruit juices deliver high concentrations of fructose without the fiber found in whole fruit.
Furthermore, prolonged sitting counteracts the benefits of a morning workout, keeping insulin sensitivity suppressed throughout the day. Chronic sleep deprivation of around five hours a night further impairs glucose regulation. Crucially, a normal body mass index does not guarantee protection. South Asians and other populations can accumulate visceral fat around internal organs despite having a slim exterior appearance, a phenomenon driven by metabolically active deep fat.
The Danger of Untreated Fibrosis and Missed Follow-Ups
When fat accumulation triggers persistent inflammation, it can develop into metabolic dysfunction-associated steatohepatitis, or MASH. Over time, that inflammation builds scar tissue known as fibrosis, which can advance to cirrhosis and liver cancer. Data indicate that roughly 5 percent to 18 percent of individuals with fatty liver develop cirrhosis, with liver cancer subsequently emerging annually in about 2.6 percent of that group.
Despite these severe risks, patient follow-up remains alarmingly low. An analysis of 1,000 fatty liver patients conducted by the National Institute of Health of the Korea Disease Control and Prevention Agency revealed that 79.9 percent discovered the condition incidentally during health screenings. Yet 42.3 percent of diagnosed patients took no follow-up action, with 41.6 percent citing the belief that their condition lacked seriousness.
The fatty liver noted on a health screening report is the first warning from the liver.
Lee Moon-hyung, professor of gastroenterology at Kyung Hee University Hospital at Gangdong, via Health Chosun
Cardiovascular Complications and Clinical Management Strategies
The threat extends far beyond the liver itself. Systemic metabolic abnormalities—including insulin resistance, elevated blood triglycerides, and low HDL cholesterol—place a heavy burden on vascular health. Consequently, cardiovascular events such as myocardial infarction and stroke represent leading causes of death among patients with MASLD, outpacing liver-related mortality in many study cohorts. Chronic kidney disease and type 2 diabetes also share this interconnected metabolic pathway.
Medical evaluation often begins with routine blood panels and the FIB-4 score, which estimates advanced fibrosis risk using age and blood parameters. Doctors may also order an abdominal ultrasound or a noninvasive liver fibrosis test like a FibroScan to measure liver stiffness without a tissue biopsy. According to public health data, achieving a modest weight reduction of 3 percent to 5 percent can decrease accumulated liver fat, while losing 7 percent to 10 percent helps improve steatohepatitis and fibrosis.
High-risk groups with obesity or diabetes should check the condition of their liver through liver fibrosis testing and regular follow-up.
Lee Moon-hyung, professor of gastroenterology at Gangdong Kyung Hee University Hospital, via Sports Chosun